Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

NHS officials estimate that around 50 people a year will receive treatment now that it has been approved for use for certain ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

A £1.65 million treatment has been approved for use for some NHS patients, offering hope of a cure to those with an inherited ...